NeuroOne Medical Technologies Corp NMTC.OQ NMTC.O is expected to show a rise in quarterly revenue when it reports results on August 14 for the period ending June 30 2025
The Eden Prairie Minnesota-based company is expected to report a 120.4% increase in revenue to $1.82 million from $825.78 thousand a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for NeuroOne Medical Technologies Corp is for a loss of 5 cents per share.
The one available analyst rating on the shares is "strong buy".
The average consensus recommendation for the advanced medical equipment & technology peer group is also "Strong Buy".
Wall Street's median 12-month price target for NeuroOne Medical Technologies Corp is $1.45, about 49.1% above its last closing price of $0.74
This summary was machine generated August 12 at 13:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)